The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China: Analysis of the Results From the Chinese National Stroke Registry (CNSR)
Abstract
Background and Purpose—: Little is known about intravenous recombinant tissue plasminogen activator (rtPA) use in China. By accessing the Chinese National Stroke Registry (CNSR), the rate of intravenous rtPA use was reviewed. We specifically examined the issues of prehospital and in-emergency department delay and compared them with the published data from developed countries. Methods—: Funded by Chinese government, CNSR is the only nationwide stroke registry that includes 132 urban hospitals. All patients eligible for intravenous rtPA were included for analysis. We then compared the onset-to-needle time and door-to-needle time in the emergency department in China with those in developed countries. Results—: From September 2007 to August 2008, 14 702 patients with ischemic stroke were entered into CNSR. Among 11 675 patients with known time of stroke onset, 2514 (21.5%) presented to the emergency department within 3 hours, 1469 (12.6%) were eligible for thrombolytic treatment, and 284 (2.4%) were finally treated, 181 (1.6%) of them with intravenous rtPA. The median onset-to-needle time was 180 (interquartile range, 150 to 228) minutes; the median door-to-needle time was 116 (interquartile range, 70 to 150) minutes; the median imaging-to-needle time was 90 (interquartile range, 60 to 129) minutes. Patients who were younger, presented to the emergency department quicker, with higher National Institutes of Health Stroke Scale scores, having higher income, and better education had a better chance of receiving intravenous rtPA. Conclusions—: Approximately 1 in 5 patients with stroke presenting within 3 hours received thrombolytic therapy. The onset-to-needle time, door-to-needle time, and especially imaging-to-needle time were significantly longer than those in developed countries. Reducing prehospital and in-emergency department response time would help increase intravenous rtPA use in China.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Cited by
Stroke in China: advances and challenges in epidemiology, prevention, and management
Wu, S., Wu, B., Liu, M., Chen, Z., Wang, W., Anderson, C. S., Sandercock, P., Wang, Y., Huang, Y., Cui, L., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30500-3 · Cited by 1,589
Self-citationEuropean Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke
Berge, E., Whiteley, W., Audebert, H., De Marchis, G., Fonseca, A. C., Padiglioni, C., Pérez de la Ossa, N., Strbian, D., Tsivgoulis, G., & Turc, G. (2021) · European Stroke Journal · doi:10.1177/2396987321989865 · Cited by 1,355
Stroke and Stroke Care in China: Huge Burden, Significant Workload, and a National Priority
Liu, L., Wang, D., Wong, K. S. L., & Wang, Y. (2011) · Stroke · doi:10.1161/strokeaha.111.635755 · Cited by 727
Self-citationHe, J., Zhang, Y., Xu, T., Zhao, Q., Wang, D., Chen, C.-S., Tong, W., Liu, C., Xu, T., Ju, Z., et al. (2014) · JAMA · doi:10.1001/jama.2013.282543 · Cited by 452
Self-citationLow-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke
Anderson, C. S., Robinson, T., Lindley, R. I., Arima, H., Lavados, P. M., Lee, T.-H., Broderick, J. P., Chen, X., Chen, G., Sharma, V. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515510 · Cited by 442
Self-citation
Metadata
- Authors
- Wang, Y., Liao, X., Zhao, X., Wang, D. Z., Wang, C., Nguyen-Huynh, M. N., Zhou, Y., Liu, L., Wang, X., Liu, G., Li, H., & Wang, Y.
- Venue
- Stroke
- Published
- 2011-06
- Volume
- 42
- Issue
- 6
- Pages
- 1658-1664
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2043976791
- Cited by
- 230
- References
- 1
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.